NCT06980532View on ClinicalTrials.gov

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

December 30, 2028

Study Completion Date

December 30, 2028

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Glumetinib Combined with Fruquintinib

"Fruquintinib: 3mg, po.qd, d1-14，q3w;~Guemitinib:~Grade 1:200mg, po, qd, q3w; Grade 2:250mg, po, qd, q3w; Phase I: The dose of Glumetinib (200 mg → 250 mg) is dynamically adjusted using the 3+3 dose-escalation rule to determine the optimal dose of Fruquintinib.~Phase II: The RP2D (Recommended Phase II Dose) of Glumetinib identified in Phase I is continued in combination with Fruquintinib."

Trial Locations (1)

430000

RECRUITING

Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Liu Huang

OTHER